

To  
Editor-In-Chief

At the outset, we thank the reviewers for their diligent review to enhance the value of this publication. We have now addressed all the points raised and summarized these in the letter below. These corrections/modifications have also been incorporated in the revised manuscript. We hope that the manuscript will now be suitable for publication.

W J Gastroenterol Reviewer comments	Author Responses
<b>Reviewer: 02994003</b>	
This manuscript is well written with clear idea.	-
It is better if this manuscript included one diagrammatic figure.	The suggested change has been incorporated. We have added Figure 1.
Please modify references according to the journal style	All references have been reviewed again and stylized as per the journal style.
<b>Reviewer: 00006518</b>	
There are multiple wrong citations in the context (begins from reference 13 where 'APRI' cited in reference 17) probably caused by typos or inadequate proofreading for the submitted manuscript.	The manuscript and references have been reviewed again and citations have been corrected
Please add treatment regimens 'not recommended' (per Table 1 definitions) in Table 3 to Table 7 including pegylated interferon, boceprevir, and telaprevir for each genotype where appropriate.	The suggested change has been incorporated.
<b>Reviewer: 03262371</b>	
There are some special groups that should be more noted. Regardless of HCV genotype, previous history of treatment. Co-infection with HIV/HBV/TB. Conditions like renal failure, renal and/or liver transplantation, hepatocellular carcinoma, and etc. are very important and they should be highlighted in separate section in such consensuses.	The suggested special groups have been highlighted for each regimen under each genotype, based on the available evidences in the literature.
I suggest that authors speak more about possible plans of HCV eradication in CIS area	Please note that this is not within the scope of the objectives of the expert panel meeting.
<b>Reviewer: 02528812</b>	
It is a very in-depth study, well written and well organized	-
Authors should include the following: 1) Emerging drug resistance and strategic planning to avoid the same.	A small section on emerging drug resistance and strategic planning has been included before the summary section.
2) The recent developments with respect to the treatment of hepatitis C infection with DAA, published during the period 2018-2019.	New literature search was conducted, and all relevant new studies and corresponding data has been included in the manuscript.
5) Minor degree of language polishing.	New language review has been done for further refinement.

The references are not according to the format of the journal. Reference section: PMID and DOI should be included	The references have been reviewed again and reformatted as per the journal style.
<b>Reviewer: 03475636</b>	
Please provide more detailed treatments for those patients with significant CKd, eGFR<30 mL/min/BSA and ESRD on dialysis? These have not been described in table or text in details	The suggested special groups have been highlighted for each regimen under each genotype, based on the available evidences in the literature
Please additional clarify “four countries in the Ukraine/CIS region” in detail	The four countries included Uzbekistan, Ukraine, Belarus, and Kazakhstan, and have been highlighted in the revised manuscript.
Where was the meeting located? On 9 April 2018; what was the name of the meeting? Need to clarify in detail.	The meeting was conducted on the side lines of the EASL 2018 conference at Holiday Inn Paris - St. Germain des Près. The same has been highlighted in the revised manuscript.
Some revision of the English language is needed. To mention as a few as below: “socioeconomical barriers” is not correct term. “an useful marker” is not correct in grammar.	New language review has been done for further refinement.
<b>Reviewer: 01557574</b>	
This manuscript should be published at WJG. There is general information and it is well documented	-
<b>General Comments/Comments by Ma Ruoyu</b>	
Please provide language certificate letter by professional English language editing companies	Language certificate has been provided along with the revised manuscript.
In order to attract readers to read your full-text article, we request that the author make an audio file describing your final core tip, it is necessary for final acceptance. Please refer to Instruction to authors on our website or attached Format for detailed information. The accepted formats are mp3 or wma	The suggested audio file has been provided along with the revised manuscript.
Author Affiations: Please rearrange all the authors’ affiliations with Department, University or Institute, City, Postcode, Country, etc. (without any symbol or figure like * or <sup>1</sup> , postcode must be there) Such as: full name, address	All author affiliations updated
ORCID Number: Full name (number); ...	The ORCID numbers are uploaded in submission system.
Supported by Mylan....: You need to provide the grant application form(s) or certificate of funding agency for every grant, or we will delete the part of "Supported by...".	There is no grant application number, hence it is being removed.
Corresponding author: Please provide the Corresponding author’s name, title, and detailed address	The suggested change has been incorporated.

<p>Please distinguish between the title of the article series. Three levels of subtitles are allowed: (1) First subtitle: All in bold and capital; (2) Second subtitle: All in bold and italic; and (3) Third subtitle: All in bold.</p> <p>Please provide the decomposable figure of all the figures, whose parts are all movable and editable, organize them into a PowerPoint file, and submit as “Manuscript No. - image files.ppt” on the system. Make sure that the layers in the PPT file are fully editable. For figures, use distinct colors with comparable visibility and consider colorblind individuals by avoiding the use of red and green for contrast</p>	<p>The suggested changes have been incorporated.</p>
<p>References: Please check and confirm that there are no repeated references!</p> <p>Please add PubMed citation numbers (<b>PMID</b> NOT PMCID) and DOI citation to the reference list and <b>list all authors</b>. Please revise throughout. The author should provide the first page of the paper without PMID and DOI.</p> <p>PMID (<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed</a>) (Please begin with PMID: ) DOI (<a href="http://www.crossref.org/SimpleTextQuery/">http://www.crossref.org/SimpleTextQuery/</a>) (Please begin with DOI: 10.**)</p>	<p>All references are checked, no duplication of references.</p> <p>Wherever applicable, we have provided the PMID and DOI.</p>
<p>Figures/Tables: For figures, use distinct colors with comparable visibility and consider colorblind individuals by avoiding the use of red and green for contrast.</p> <p>Please don't include abbreviations in the title of the figure/table.</p> <p>Please explain all the abbreviations in the figure/table legends as full name (abbreviation).</p> <p>Please explain all the abbreviations of each figure/table under each piece of figure/table legends.</p> <p>Please don't include any *, #, ...in your manuscript; Please use superscript numbers for illustration; and for statistical significance, please use superscript letters.</p> <p>Please create another file for all the supplementary figures and tables and name the file as “xxxxx-Supplementary material.pdf”</p>	<p>The suggested changes have been incorporated.</p>

Your manuscript should be prepared with Word-processing Software, using 12 pt Book Antiqua font and 1.5 line spacing with ample margins.	
Please provide the decomposable figure of all the figures, whose parts are all movable and editable, organize them into a PowerPoint file, and submit as “Manuscript No. - image files.ppt” on the system. Make sure that the layers in the PPT file are fully editable. For figures, use distinct colors with comparable visibility and consider colorblind individuals by avoiding the use of red and green for contrast.[MR1]	Figure 1 has been removed from Manuscript file, edited as suggested and uploaded as PPT file in submission system.

Sincerely  
Massimo Giuseppe Colombo,  
Consultant, Research and Clinical  
Center, Department of Medicine,  
Humanitas Hospital, Via Manzoni 56 Rozzano,  
Italy  
[Email: Massimo.colombo@humanitas.it](mailto:Massimo.colombo@humanitas.it)  
Phone: +393355719512